This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEE2B11L_M.jpg
Biogen announced earnings per share of $4.58 on revenue of $2.85B. Analysts polled by Investing.com anticipated EPS of $4.75 on revenue of $2.8B.
Biogen shares are up 13% from the beginning of the year, still down 25.94% from its 52 week high of $374.99 set on February 5, 2020. They are outperforming the Nasdaq 100 which is up 4.41% from the start of the year.
Biogen’s report follows an earnings beat by J&J on January 26, who reported EPS of $1.86 on revenue of $22.48B, compared to forecasts EPS of $1.82 on revenue of $21.66B.
Abbott Labs had beat expectations on January 27 with fourth quarter EPS of $1.45 on revenue of $10.7B, compared to forecast for EPS of $1.35 on revenue of $9.94B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
